Trial · NCT01692496
Results by group31
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 31
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-free Survival (PFS) Assessed 12 Weeks After Start of Treatment | Pazopanib | Cohort A | 54.1 | 95% Confidence Interval 38 to 70.2 | percentage of participants |
| Progression-free Survival (PFS) Assessed 12 Weeks After Start of Treatment | Pazopanib | Cohort B | 46.2 | 95% Confidence Interval 19.1 to 73.3 | percentage of participants |
| Overall Progression Free Survival (Median PFS) | Pazopanib | Pazopanib | 12.14 | 95% Confidence Interval 7.75 to 16.53 | Weeks |
| Overall Progression Free Survival (Median PFS) | Pazopanib | Cohort A | 15 | 95% Confidence Interval 8.19 to 21.8 | Weeks |
| Overall Progression Free Survival (Median PFS) | Pazopanib | Cohort B | 10.29 | 95% Confidence Interval 5.09 to 15.49 | Weeks |
| Percentage of Patients With Objective Tumor Response (OR) | Pazopanib | 6 weeks OR (PP population) | 8 | 95% Confidence Interval 0.5 to 15.5 | Percentage of patients |
| Percentage of Patients With Objective Tumor Response (OR) | Pazopanib | 12 weeks OR (PP population) | 4 | 95% Confidence Interval 1.4 to 9.4 | Percentage of patients |
| Overall Survival (OS) | Pazopanib | Pazopanib | 70.43 | 95% Confidence Interval 44.92 to 95.94 | Weeks |
| Overall Survival (OS) | Pazopanib | Cohort A | 70.43 | 95% Confidence Interval 42.69 to 98.1 | Weeks |
| Overall Survival (OS) | Pazopanib | Cohort B | 71.29 | 95% Confidence Interval 31.21 to 111.36 | Weeks |
| Clinical Benefit Rate | Pazopanib | Pazopanib | 26 | 95% Confidence Interval 13.8 to 38.2 | Percentage of patients |
| Clinical Benefit Rate | Pazopanib | Cohort A | 32.4 | 95% Confidence Interval 17.3 to 47.5 | Percentage of patients |
| Clinical Benefit Rate | Pazopanib | Cohort B | 7.7 | 95% Confidence Interval 6.8 to 22.2 | Percentage of patients |
| Growth Modulation Index (GMI) | Pazopanib | Pazopanib | 0.4 | 95% Confidence Interval 0.1 to 18.6 | Arbitrary units |
| Growth Modulation Index (GMI) | Pazopanib | Cohort A | 0.7 | 95% Confidence Interval 0.1 to 18.6 | Arbitrary units |
| Growth Modulation Index (GMI) | Pazopanib | Cohort B | 0.2 | 95% Confidence Interval 0.1 to 1.1 | Arbitrary units |
| Safety Profile (According CTCAE, Version 4.0) | Pazopanib | AEs Pazopanib | 52 | Patients | |
| Safety Profile (According CTCAE, Version 4.0) | Pazopanib | AEs Cohort A | 37 | Patients | |
| Safety Profile (According CTCAE, Version 4.0) | Pazopanib | AEs Cohort B | 15 | Patients | |
| Safety Profile (According CTCAE, Version 4.0) | Pazopanib | related AEs Pazpanib | 46 | Patients |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01692496/results